Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

1. Expression and prognostic impact of CD73 in classical Hodgkin lymphoma.Annals of hematology · 2026
   Article
2. Methodological guidelines for P2X receptor assays and data interpretation.Cell death & disease · 2026
   Review
3. Purin Metabolism Is Crucial for Regulatory T Cell Stability and Function.European journal of immunology · 2025
   Review
4. Adeno-associated viral vectors encoding anti-P2X7 nanobodies reduce graft-versus-host disease in a humanised mouse model.Clinical & translational immunology · 2025
   Article
5. NAD+ metabolism and therapeutic strategies in cardiovascular diseases.Atherosclerosis plus · 2024
   Review
6. Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies.Cancer cell international · 2024
   Review
7. Anti-inflammatory potency of novel ecto-5'-nucleotidase/CD73 inhibitors in astrocyte culture model of neuroinflammation.European journal of pharmacology · 2023
   Article
8. The Clinical Significance of CD73 in Cancer.International journal of molecular sciences · 2023
   Review
9. Reviving a Classic Antigen with a Cutting-Edge Approach: Nanobodies for HER2+ Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2023
   Review
10. Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far?International journal of molecular sciences · 2023
    Review
11. A Possible Causal Involvement of Neuroinflammatory, Purinergic P2X7 Receptors in Psychiatric Disorders.Current neuropharmacology · 2022
    Article
12. Nanobodies: new avenue to treat kidney disease.Cell and tissue research · 2021
    Review
13. FluoSTEPs: Fluorescent biosensors for monitoring compartmentalized signaling within endogenous microdomains.Science advances · 2021
    Article
14. Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review).International journal of molecular medicine · 2021
    Review
15. Nanobody: a promising toolkit for molecular imaging and disease therapy.EJNMMI research · 2021
    Review
16. Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor.Biomolecules · 2021
    Review
17. P2X7 Receptors as a Therapeutic Target in Cerebrovascular Diseases.Frontiers in molecular neuroscience · 2020
    Article
18. Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets.Frontiers in immunology · 2019
    Review
19. P2YAmerican journal of translational research · 2019
    Article
20. Labeling single domain antibody fragments withNuclear medicine and biology
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as